PLX73086

Phase 1Small molecule

Daiichi Sankyo

PLX73086 is one of 13 small molecule programs targeting Giant Cell Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell TumorActive, not recruiting

Giant Cell TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Giant Cell Tumor

#DrugCompanyPhaseTrials

IC-Green

CCHX Technologies Inc.

Approved

2 2

Zometa

Pfizer

Phase 3

1 3

Turalio

Daiichi Sankyo

Phase 2

2 4

Xgeva

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Approved

1 5

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 6

Emactuzumab

Roche

Phase 3

1 7

Narlumosbart

SShanghai JMT-Bio Inc.

Phase 3

1 8

Prolia

Amgen

Preclinical

7 9

Romvimza

DDeciphera Pharmaceuticals, LLC

Phase 2

1 10

Pimicotinib（absk021）

AAbbisko Therapeutics Co, Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Giant Cell Tumor1 trial

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02673736·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PLX73086. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PLX73086 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PLX73086. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Daiichi Sankyo

PLX73086

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Giant Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News